

# Simon Weonsang Ro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8228320/publications.pdf>

Version: 2024-02-01

29  
papers

726  
citations

686830

13  
h-index

552369

26  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1144  
citing authors

#	ARTICLE	IF	CITATIONS
1	Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. <i>Biology</i> , 2022, 11, 585.	1.3	5
2	Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. <i>BMC Cancer</i> , 2022, 22, 423.	1.1	10
3	Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS). <i>Cancers</i> , 2022, 14, 2733.	1.7	7
4	Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2021, 21, 1-11.	0.3	4
5	MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3026.	1.7	104
6	YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. <i>Hepatology</i> , 2021, 74, 2605-2621.	3.6	22
7	Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer. <i>Translational Oncology</i> , 2021, 14, 101158.	1.7	7
8	c-Myc-driven Hepatocarcinogenesis. <i>Anticancer Research</i> , 2021, 41, 4937-4946.	0.5	14
9	Pharmacological Inhibition of Sonic Hedgehog Signaling Suppresses Tumor Development in a Murine Model of Intrahepatic Cholangiocarcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13214.	1.8	4
10	Genetically Engineered Mouse Models for Liver Cancer. <i>Cancers</i> , 2020, 12, 14.	1.7	23
11	Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 249-258.	1.9	13
12	High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2019, 20, 581.	1.8	35
13	Barrier to autointegration factor 1, procollagen $\alpha$ 1(I) lysine 2-oxoglutarate 5-hydroxylase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma. <i>Hepatology</i> , 2018, 67, 1360-1377.	3.6	90
14	Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4691-4696.	3.3	56
15	Transforming Growth Factor- $\beta$ 2 Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail. <i>Gastroenterology</i> , 2017, 153, 1378-1391.e6.	0.6	71
16	Pro-tumorigenic roles of TGF- $\beta$ 2 signaling during the early stages of liver tumorigenesis through upregulation of Snail. <i>BMB Reports</i> , 2017, 50, 599-600.	1.1	5
17	Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy. <i>International Journal of Cancer</i> , 2016, 138, 1601-1608.	2.3	26
18	Synergic chemoprevention with dietary carbohydrate restriction and supplementation of AMPK-activating phytochemicals. <i>European Journal of Cancer Prevention</i> , 2016, 25, 54-64.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. BMC Gastroenterology, 2016, 16, 13.	0.8	16
20	Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model. Journal of Hepatology, 2016, 64, 618-627.	1.8	88
21	Comparison of liver oncogenic potential among human RAS isoforms. Oncotarget, 2016, 7, 7354-7366.	0.8	11
22	Making cancer fat: reprogramming of lipid metabolism by CD147 in hepatocellular carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 380-382.	0.7	3
23	Transgenic mouse model expressing P53R172H, luciferase, EGFP and KRASG12D in a single open reading frame for live imaging of tumor. Scientific Reports, 2015, 5, 8053.	1.6	10
24	Analysis of miRNA expression patterns in human and mouse hepatocellular carcinoma cells. Hepatology Research, 2015, 45, 1331-1340.	1.8	7
25	Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2015, 76, 257-267.	1.1	5
26	Inhibition of tumour angiogenesis and growth by small hairpin <sc>HIF</sc> and <sc>IL</sc> in hepatocellular carcinoma. Liver International, 2014, 34, 632-642.	1.9	27
27	Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1481-1491.	2.2	12
28	Sleeping Beauty transposon system harboring HRAS, c-Myc and shp53 induces sarcomatoid carcinomas in mouse skin. Oncology Reports, 2013, 29, 1293-1298.	1.2	8
29	Investigation of Oncogenic Cooperation in Simple Liver-Specific Transgenic Mouse Models Using Noninvasive In Vivo Imaging. PLoS ONE, 2013, 8, e59869.	1.1	32